Natco Pharma Ltd

₹ 892 2.31%

14 Jan

🔗 Website | BSE: 524816 | NSE: NATCOPHARM

Market Cap16,019

Current Price892

High / Low1,341

Stock P/E10.6

Book Value462

Dividend Yield0.67

ROCE31.8

ROE27.5

ABOUT

NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas.[1]NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business.[2]

Stock Analysis

### Description NATCO Pharma Limited is a vertically integrated, research and development-focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. ### Key Growth Triggers Its international business focuses on Para IV and first-to-file molecules, with plans to expand into emerging markets like MENA, LATAM, and Southeast Asia. ### Order Book Currently no data available for Order Book. ### Key Red Flags Ongoing litigation proceedings are continuing with an outcome yet to be determined, which poses a potential risk to the company's financial performance. While the company states no material financial impact from the recent news article as of now, the uncertainty remains. ### Key Dates To Watch Currently no data available for Key Dates To Watch.

Peer Comparison

S.No.	Name	Current Price (Rs.)	Price to Earning	Market Capitalization (Rs.Cr.)	Dividend yield (%)	Net Profit latest quarter (Rs.Cr.)	YOY Quarterly profit growth (%)	Sales latest quarter (Rs.Cr.)	YOY Quarterly sales growth (%)	Return on capital employed (%)	Sales (Rs.Cr.)	OPM (%)	Profit after tax (Rs.Cr.)	Profit after tax latest quarter (Rs.Cr.)	Price to book value	Return on assets (%)	Debt to equity
1.	Sun Pharma.Inds.	1700.70	35.33	407795.42	0.94	3124.95	2.56	14478.31	8.93	20.21	54964.01	30.12	11543.96	3117.95	5.24	12.97	0.07
2.	Divi's Lab.	6355.50	67.92	168791.98	0.47	689.00	35.10	2715.00	16.12	20.44	10029.00	32.37	2485.00	689.00	10.95	13.53	0.01
3.	Torrent Pharma.	4003.70	62.56	135529.20	0.80	591.00	32.49	3302.00	14.30	27.05	12248.00	32.60	2166.53	600.17	16.04	13.26	0.33
4.	Cipla	1434.50	21.31	115930.82	0.91	1353.37	3.73	7589.44	7.64	22.72	28349.57	25.40	5441.14	1351.17	3.52	14.72	0.01
5.	Lupin	2195.90	23.22	100409.83	0.55	1484.83	73.34	7047.51	24.23	21.30	24750.69	27.25	4324.63	1477.92	5.11	12.41	0.32
6.	Dr Reddy's Labs	1186.50	17.17	99107.92	0.67	1336.80	7.28	8828.30	9.83	22.69	34310.00	24.64	5772.20	1347.10	2.75	12.95	0.16
7.	Mankind Pharma	2244.40	53.01	92685.55	0.04	520.18	-22.00	3697.16	20.77	15.98	13545.67	24.12	1748.55	511.51	6.06	8.89	0.55
8.	Natco Pharma	891.95	10.55	16018.89	0.67	500.90	-24.23	1264.30	-2.19	31.80	4022.00	41.84	1518.00	500.90	1.93	23.99	0.03

Quarterly Results

Figures in Cr.

	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	351	413	781	1,048	930	625	965	1,237	1,293	408	1,157	1,193	1,264
YOY Sales Growth %	6.27%	-22%	51.95%	30.11%	165.02%	51.4%	23.5%	17.99%	38.91%	-34.82%	19.96%	-3.57%	-2.19%
Expenses	281	346	454	545	488	387	512	474	502	378	596	653	712
Material Cost %	23.27%	28.5%	26.27%	16.88%	19.44%	17.7%	10.98%	11.77%	12.05%	17.25%	19.15%	15.4%	12.22%
Employee Cost %	27.97%	22.25%	12.46%	11.37%	11.48%	16.62%	12.96%	9.72%	10.27%	30.32%	11.98%	12.03%	14.13%
Operating Profit	70	68	328	504	442	238	453	763	791	29	561	540	552
OPM %	20%	16%	42%	48%	48%	38%	47%	62%	61%	7%	48%	45%	44%
Other Income	16	19	18	15	25	30	36	40	51	168	62	60	93
Exceptional items	—	—	—	—	—	—	—	—	—	—	—	—	—
Other income normal	16	19	18	15	25	30	36	40	51	168	62	60	93
Interest	2	3	1	3	3	4	4	4	3	3	9	3	12
Depreciation	38	38	38	40	40	40	52	40	42	44	94	54	48
Profit before tax	46	45	306	475	424	224	432	758	797	150	521	543	586
Tax %	19%	17%	17%	15%	15%	14%	19%	16%	17%	17%	18%	15%	15%
Net Profit	38	37	254	405	360	192	349	636	661	125	428	464	501
EPS in Rs	2.07	2.04	13.92	22.63	20.11	10.72	19.49	35.53	36.91	6.97	23.9	25.91	27.97

Profit & Loss

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	622	716	1,059	1,958	2,091	1,986	1,790	1,654	1,768	2,351	3,569	4,094	4,022
Sales Growth %	11.56%	14.98%	48.03%	84.86%	6.81%	-5.02%	-9.87%	-7.64%	6.91%	32.99%	51.8%	14.73%	—
Expenses	436	487	778	1,266	1,163	1,170	1,212	1,236	1,555	1,506	1,929	1,950	2,339
Material Cost %	24.22%	23.86%	24.2%	29.25%	18.58%	17.07%	22.18%	30.24%	30.24%	22.53%	16.1%	14.49%	—
Raw material cost	167	179	304	590	413	365	453	547	540	495	557	582	—
Change in inventory	-16	-9	-48	-17	-25	-26	-56	-47	-6	35	17	12	—
Manufacturing Cost %	15.07%	12.66%	14.83%	7.74%	8.43%	9.03%	11.01%	10.5%	12.73%	9.88%	7.53%	7.59%	—
Employee Cost %	15.14%	16.24%	16.24%	11.86%	14.93%	17.13%	19.9%	22.99%	23.22%	18.12%	12.75%	12.59%	—
Other Cost %	15.58%	15.3%	18.23%	15.8%	13.67%	15.66%	14.63%	11.01%	21.76%	13.54%	17.68%	12.95%	—
Operating Profit	187	229	281	692	928	816	578	418	213	845	1,640	2,144	1,683
OPM %	30%	32%	26%	35%	44%	41%	32%	25%	12%	36%	46%	52%	42%
Other Income	16	-2	13	13	39	130	124	101	95	86	102	321	383
Exceptional items	1	-12	0	0	10	14	16	32	43	18	-3	88	—
Other income normal	15	11	13	13	29	116	108	69	52	68	105	233	—
Interest	34	30	22	18	15	19	21	11	13	9	14	20	26
Depreciation	27	42	50	54	66	80	98	115	138	151	172	220	239
Profit before tax	141	154	222	634	888	847	583	392	156	771	1,555	2,226	1,800
Tax %	22%	1%	20%	22%	21%	21%	19%	21%	11%	17%	16%	17%	—
Net Profit	110	153	176	495	698	667	474	310	139	637	1,307	1,850	1,518
Exceptional items AT	1	-10	0	0	8	11	13	24	34	15	-2	72	—
Profit excl Excep	109	162	176	495	690	657	462	285	105	622	1,309	1,778	—
Profit for PE	109	162	176	495	690	657	462	285	105	622	1,309	1,778	—
Profit for EPS	110	153	176	495	698	667	474	310	139	637	1,307	1,850	—
EPS in Rs	6.66	9.2	10.13	28.39	37.84	36.48	26.06	16.97	7.62	34.9	72.95	103.31	84.75
Dividend Payout %	15%	11%	12%	24%	22%	17%	26%	31%	59%	16%	13%	6%	—

Balance Sheet

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	33	33	35	35	37	36	36	36	36	36	36	36	36
Reserves	700	846	1,302	1,665	3,088	3,527	3,833	4,055	4,155	4,666	5,556	7,298	8,235
Borrowings	237	309	110	221	173	384	314	256	400	161	366	275	256
Long term Borrowings	95	96	0	0	0	0	1	0	0	0	0	0	0
Short term Borrowings	99	169	96	221	173	384	313	255	389	160	363	273	253
Lease Liabilities	—	—	—	—	—	—	—	—	—	—	—	—	—
Other Borrowings	44	44	14	0	0	0	0	0	0	0	0	0	—
Other Liabilities	206	207	396	427	438	408	463	405	387	525	596	661	1,367
Trade Payables	99	115	270	251	245	202	234	140	141	182	183	225	456
Advance from Customers	15	20	24	14	18	19	0	18	4	95	84	83	—
Other liability items	92	71	102	161	174	188	229	248	241	247	329	354	911
Total Liabilities	1,176	1,395	1,843	2,347	3,736	4,356	4,647	4,752	4,978	5,388	6,554	8,270	9,894
Fixed Assets	529	573	706	829	1,015	1,215	1,574	2,006	2,174	2,234	2,287	2,517	2,515
Land	79	100	134	172	203	235	249	248	264	286	369	526	—
Building	185	216	261	299	358	437	617	889	964	1,050	1,098	1,130	—
Plant Machinery	390	427	531	622	769	924	1,130	1,388	1,551	1,625	1,687	1,812	—
Equipments	3	3	3	3	4	4	4	4	4	5	5	4	—
Furniture & fittings	—	—	—	—	—	—	—	—	—	—	—	—	—
Vehicles	10	11	14	17	20	22	24	24	27	24	27	33	—
Intangible Assets	0	0	0	0	0	0	0	0	0	0	0	0	101
Other fixed assets	9	9	11	13	15	19	52	55	89	82	81	183	—
Gross Block	691	783	976	1,151	1,400	1,678	2,134	2,678	2,978	3,157	3,360	3,784	—
Accumulated Depreciation	162	210	270	322	384	463	559	672	804	923	1,073	1,267	—
CWIP	93	101	212	336	480	638	518	223	129	63	134	225	254
Investments	89	131	94	95	150	244	191	337	550	658	742	855	1,060
Other Assets	465	590	831	1,087	2,091	2,259	2,363	2,186	2,125	2,434	3,392	4,673	6,065
Inventories	162	198	352	337	426	508	524	769	698	616	597	642	665
Trade receivables	116	189	256	469	606	492	537	400	576	793	1,077	1,178	1,574
Receivables under 6m	—	—	—	—	—	—	—	—	—	—	—	—	—
Receivables over 6m	—	—	—	—	—	—	—	—	—	—	—	—	—
Prow for Doubtful	—	—	—	—	—	—	—	—	—	—	—	—	—
Cash Equivalents	8	7	40	25	172	263	54	263	101	412	865	1,857	2,413
Loans & Advances	—	—	—	—	—	—	—	—	—	—	—	—	—
Other Assets items	—	—	—	—	—	—	—	—	—	—	—	—	—
Total Assets	1,176	1,395	1,843	2,347	3,736	4,356	4,647	4,752	4,978	5,388	6,554	8,270	9,894

Cash Flows

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	172	125	190	330	476	699	422	184	58	784	1,196	1,662
Profit from operations	198	217	303	734	962	860	628	451	274	856	1,706	2,206
Receivables	11	-72	-76	-237	-149	121	-54	129	-222	-204	-292	-103
Inventory	-34	-37	-143	15	-89	-82	-16	-245	72	82	38	-56
Payables	4	20	151	-19	-6	-43	35	-95	2	41	1	43
Loans Advances	12	5	86	-1	-1	-2	-5	-5	3	0	0	0
Other WC items	14	11	-87	-40	-36	21	-61	25	-39	158	-5	-83
Working capital changes	6	-72	-68	-282	-281	14	-101	-190	-184	77	-258	-199
Direct taxes	-32	-20	-45	-122	-204	-175	-105	-77	-32	-148	-252	-345
Cash from Investing Activity	-131	-148	-248	-291	-1,131	-645	-165	-3	-92	-437	-960	-1,444
Fixed assets purchased	-96	-107	-153	-277	-424	-452	-355	-243	-235	-147	-337	-508
Fixed assets sold	0	2	1	0	18	18	22	45	54	30	2	95
Investments purchased	-0	0	0	0	-48	-111	-64	-58	-18	-60	-149	-255
Investments sold	2	3	-40	16	0	20	120	7	12	15	133	157
Interest received	3	0	2	8	10	52	89	68	50	41	48	125
Redeemp Cnce of Shares	—	—	—	—	—	—	—	—	—	—	—	—
Acquisition of companies	0	0	0	-14	-7	0	0	0	0	0	0	0
Other investing items	-1	-0	-62	-21	-674	-129	29	256	207	-230	-586	-1,051
Cash from Financing Activity	-41	23	151	-46	652	-52	-261	-183	36	-347	-237	-212
Redemption of debentures	—	—	—	—	—	—	—	—	—	—	—	—
Proceeds from borrowings	31	115	0	125	0	212	0	0	134	0	203	0
Repayment of borrowings	-130	-43	-130	-14	-48	0	-80	-57	0	-229	0	-89
Interest paid fin	-32	-29	-26	-15	-15	-18	-20	-11	-14	-8	-14	-14
Dividends paid	-19	-20	-26	-141	-181	-111	-154	-114	-82	-100	-171	-108
Financial liabilities	0	0	0	0	0	0	-1	-1	-2	-2	-2	-2
Other financing items	0	0	0	0	-0	-135	-6	0	0	-7	-254	0
Net Cash Flow	0	-1	93	-6	-3	1	-4	-3	1	1	-1	6

Ratios

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	68	96	88	87	106	90	109	88	119	123	110	105
Inventory Days	392	424	501	215	400	547	482	562	476	424	379	395
Days Payable	240	247	385	160	231	217	215	102	96	126	116	138
Cash Conversion Cycle	220	274	205	142	275	420	376	548	499	422	373	362
Working Capital Days	20	20	86	73	222	215	310	297	268	213	153	149
ROCE %	19%	18%	18%	39%	34%	24%	14%	9%	3%	16%	29%	32%

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	48.82%	48.84%	49.76%	49.71%	49.71%	49.71%	49.71%	49.62%	49.62%	49.56%	49.56%	49.48%
Bapanna Alapati	0	0	0	0	0	0	0	0	0	0	0	0
Bapineedu Tummala	0	0	0	0	0	0	0	0	0	0	0	0
Devendranth Alapati	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Durga Devi Nannapaneni	1.94	1.94	1.98	1.98	1.98	1.98	1.98	1.98	1.98	1.98	1.98	1.98
Kantamani Ratna Kumar	0.05	0.05	0.06	0.06	0.06	0.06	0.06	0.03	0.03	0.03	0.03	0.03
Natco Aqua Limited	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Natsoft Information Systems Pvt Ltd	8.65	8.65	8.81	8.81	8.81	8.81	8.81	8.81	8.81	8.81	8.81	8.81
Ndl Infratech Private Limited	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05
Neelima Sita Nannapaneni	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Rajeev Nannapaneni	0.62	0.62	0.63	0.63	0.63	0.63	0.63	0.63	0.63	0.6	0.6	0.6
Ramakrishna Rao Nannapaneni	0.41	0.41	0.42	0.42	0.42	0.42	0.42	0.42	0.42	—	—	—
Sanjay Nannapaneni	—	—	—	—	—	—	—	—	—	0.18	0.18	0.13
Satya Vani Nannapaneni	—	—	—	—	—	—	—	—	—	0.23	0.23	0.21
Sau Family Trust	0	0	0	0	0	0	0	0	0	0	0	0
T Ananda Babu	0.26	0.26	0.26	0.23	0.23	0.23	0.23	0.23	0.23	0.23	0.23	0.23
T Anila	0.35	0.35	0.35	0.33	0.33	0.33	0.33	0.32	0.32	0.32	0.32	0.32
Time Cap Pharma Labs Private Limited	9.41	9.41	9.59	9.59	9.59	9.59	9.59	9.59	9.59	9.59	9.59	9.59
Tummala Jansi	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04
V C Nannapaneni	12.38	12.39	15.66	15.66	15.66	15.66	15.66	15.66	15.66	15.66	15.66	15.66
Venkaiah Chowdary Nannapaneni Huf	2.98	2.98	0	0	0	0	0	0	0	0	0	0
Venkata Satya Swathi Kantamani	8.76	8.76	8.92	8.92	8.92	8.92	8.92	8.92	8.92	8.9	8.9	8.9
Vidyadhari Tummala	0.24	0.24	0.25	0.25	0.25	0.25	0.25	0.21	0.21	0.21	0.21	0.21
Vistra ITCL India Limited ___	0	0	0	0	0	0	0	0	0	0	0	0
FIIs	11.73%	11.91%	11.03%	12.82%	13.72%	16.14%	17.45%	17.51%	17.94%	17.49%	15.52%	14.09%
Belgrave Investment Fund	—	—	—	—	1.88	1.92	1.92	1.92	1.92	2.31	2.31	2.31
Nomura Singapore Limited Odi	1.69	1.52	1.55	1.55	—	—	—	—	—	—	—	—
Plenty Private Equity Fii I Limited	1.73	1.74	—	—	—	—	—	—	—	—	—	—
DIIs	14.93%	15.38%	15.15%	14.01%	11.26%	9.69%	7.86%	6.75%	5.59%	5.64%	5.81%	5.87%
Icici Prudential India Opportunities Fund	—	—	3.81	—	—	—	—	—	—	—	—	—
Icici Prudential Multicap Fund	4.08	—	—	1.73	—	—	—	—	—	—	—	—
Icici Prudential S&P Bse 500 Etf	—	4.3	—	—	—	—	—	—	—	—	—	—
LIFE INSURANCE CORPORATION OF INDIA - P & GS Fund	—	4.04	—	—	—	3.86	—	3.04	2.29	—	—	—
Life Insurance Coporation Of India	4.04	—	—	—	—	—	—	—	—	—	—	—
Life Insurance Corporation of India	—	—	4.11	4.11	4.11	—	3.69	—	—	2.29	2.29	2.29
Mirae Asset Emerging Bluechip Fund	3.35	—	2.8	—	—	—	—	—	—	—	—	—
Mirae Asset Healthcare Fund	—	3.01	—	2.73	—	—	—	—	—	—	—	—
Mirae Asset Large & Midcap Fund	—	—	—	—	—	2.19	—	—	—	—	—	—
Mirae Asset Midcap Fund	—	—	—	—	2.66	—	—	—	—	—	—	—
Quant Mutual Fund - Quant Business Cycle Fund	—	—	—	1.05	—	—	—	—	—	—	—	—
Quant Mutual Fund - Quant Small Cap Fund	—	—	1.01	—	—	—	—	—	—	—	—	—
Tata Mutual Fund - Tata Small Cap Fund	—	—	—	1	—	—	—	—	—	—	—	—
Tata Mutual Fund- Tata Equity P/E Fund	—	—	—	—	1	—	—	—	—	—	—	—
Tata Mutual Fund- Tata Value Fund	—	—	—	—	—	—	—	—	—	—	—	1.2
Tata Nifty 500 Multicap India Manufacturing 50:30:___	—	—	—	—	—	—	—	1.22	—	—	—	—
Tata Nifty Midsmall Healthcare Index Fund	—	—	—	—	—	—	1.19	—	—	—	—	—
Government	—	—	—	—	—	—	—	—	—	—	—	—
Public	24.53%	23.87%	24.08%	23.48%	25.32%	24.46%	24.99%	26.13%	26.88%	27.3%	29.12%	30.56%
Others	—	—	—	—	—	—	—	—	—	—	—	—
No. of Shareholders	1,35,397	1,53,663	1,55,181	1,63,753	2,07,571	2,28,467	2,51,485	3,02,944	3,45,332	4,05,222	4,29,434	4,19,699

News & Updates

BSE Announcements

Direct from BSE filings, AI summarised

NATCO Pharma Clarifies Ongoing Litigation Status to BSE; States No Material Financial Impact

7 Jan 2026

NATCO Pharma Files Routine SEBI Compliance Certificate for Quarter Ended Dec 31, 2025

6 Jan 2026

NATCO Pharma Releases FY24-25 Sustainability Report Highlighting ESG Commitments and Strategic Growth Initiatives

5 Jan 2026

NATCO Pharma Limited Announces Trading Window Closure Ahead of Q3 FY26 Results

29 Dec 2025

NATCO Pharma: Q1 FY26 Revenue Declines 1.4%, PAT Falls 28% Amid US Pricing Pressure; Interim Dividend Declared

2 Dec 2025

Other Websites

External media mentions

Smallcaps Tumble Amid Broader Market Slump; Trade Hopes Spark Partial Recovery

12 Jan 2026

Natco Pharma Challenges Novo Nordisk Diabetes Drug Patent in India

6 Jan 2026

Indian Drug Firms Escalate Patent Wars Against Global Pharma Giants

6 Jan 2026

Shocking Find: 6 Strict Filters Uncover Just 2 'Multibagger' Stocks Out of 1000+!

31 Dec 2025

Stocks Hit W-Pattern: 6 Indian Mid/Small Caps Signal Potential Rebound!

15 Dec 2025

News Articles

Editorial & research coverage

Smallcaps Tumble Amid Broader Market Slump; Trade Hopes Spark Partial Recovery

12 Jan 2026

Indian Drug Firms Escalate Patent Wars Against Global Pharma Giants

6 Jan 2026

Shocking Find: 6 Strict Filters Uncover Just 2 'Multibagger' Stocks Out of 1000+!

31 Dec 2025

Stocks Hit W-Pattern: 6 Indian Mid/Small Caps Signal Potential Rebound!

15 Dec 2025

Natco Pharma Stock Tumbles 38%! Is Its High-Risk Strategy Doomed as Revlimid Power Fades?

3 Dec 2025

Documents

Announcements

Clarification

7 Jan - NATCO Pharma clarifies Jan 7, 2026: litigation ongoing, outcome awaited; no undisclosed information or material financial impact.

Clarification sought from Natco Pharma Ltd

7 Jan - Exchange has sought clarification from Natco Pharma Ltd on January 7, 2026, with reference to news appeared in https://economictimes.indiatimes.com/ dated January 7, 2026 quoting "HC …

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

null

Sustainability Report For The Year 2024-25

5 Jan - Filed Sustainability Report 2024–25 on January 5, 2026; covers FY Apr 1, 2024–Mar 31, 2025.

Closure of Trading Window

null

Annual Reports

FY Financial Year 2025

(from bse)

FY Financial Year 2024

(from bse)

FY Financial Year 2023

(from bse)

FY Financial Year 2022

(from bse)

FY Financial Year 2021

(from bse)

FY Financial Year 2020

(from bse)

FY Financial Year 2019

(from bse)

FY Financial Year 2018

(from bse)

FY Financial Year 2017

(from bse)

FY Financial Year 2016

(from bse)

FY Financial Year 2015

(from bse)

FY Financial Year 2014

(from bse)

FY Financial Year 2013

(from bse)

FY Financial Year 2013

(from nse)

FY Financial Year 2012

(from bse)

Credit Ratings

Rating update

28 Nov 2025 from icra

Rating update

1 Aug 2025 from icra

Rating update

29 Apr 2025 from icra

Rating update

30 Apr 2024 from icra

Rating update

28 Apr 2023 from icra

Rating update

28 Apr 2022 from icra

Concalls

Nov 2025

Transcript PPT Audio

Aug 2025

Transcript PPT Audio

Jul 2025

Transcript PPT

Jun 2025

Transcript PPT Audio

Feb 2025

Transcript PPT Audio

Jan 2025

Audio

Nov 2024

Transcript PPT Audio

Aug 2024

Transcript PPT Audio

Jun 2024

Transcript PPT

May 2024

PPT

Feb 2024

Transcript PPT Audio

Nov 2023

Transcript PPT

Aug 2023

Transcript PPT Audio

Jun 2023

Transcript PPT

Feb 2023

Transcript PPT

Nov 2022

Transcript PPT

Aug 2022

Transcript PPT

Jun 2022

Transcript PPT

Feb 2022

Transcript PPT

Nov 2021

Transcript PPT

Aug 2021

Transcript PPT

Jul 2021

Transcript PPT

Feb 2021

Transcript PPT

Nov 2020

Transcript PPT

Aug 2020

Transcript PPT

Jul 2020

Transcript PPT

Feb 2020

Transcript PPT

Nov 2019

Transcript PPT

Sep 2019

PPT

Aug 2019

Transcript

Jun 2019

Transcript PPT

Feb 2019

Transcript PPT

Nov 2018

Transcript PPT

Aug 2018

Transcript PPT

May 2018

Transcript PPT

Feb 2018

Transcript PPT

Nov 2017

Transcript PPT

Aug 2017

Transcript PPT

May 2017

Transcript

Feb 2017

Transcript PPT

Nov 2016

Transcript PPT

Sep 2016

PPT

Aug 2016

Transcript

Jun 2016

PPT

Feb 2016

PPT

Natco Pharma Ltd

ABOUT

Stock Analysis

Peer Comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

News & Updates

BSE Announcements

Other Websites

News Articles

Documents

Announcements

Annual Reports

Credit Ratings

Concalls